1165450-70-3

Basic information

• Product Name: (4R)-4-(hydroxyMethyl)-2-Pyrrolidinone
• Synonyms: (4R)-4-(hydroxyMethyl)-2-Pyrrolidinone;(R)-4-(hydroxymethyl)pyrrolidin-2-one
• CAS NO: 1165450-70-3
• Molecular Formula: C₅H₉NO₂
• Molecular Weight: 115.13046
• Mol File: 1165450-70-3.mol

Chemical Properties

• Boiling Point: 346.0±15.0 °C(Predicted)
• Appearance: /
• Density: 1.153±0.06 g/cm3(Predicted)
• PKA: 14.56±0.10(Predicted)
• CAS DataBase Reference: (4R)-4-(hydroxyMethyl)-2-Pyrrolidinone(CAS DataBase Reference)
• NIST Chemistry Reference: (4R)-4-(hydroxyMethyl)-2-Pyrrolidinone(1165450-70-3)
• EPA Substance Registry System: (4R)-4-(hydroxyMethyl)-2-Pyrrolidinone(1165450-70-3)

Safety Data

• Hazardous Substances Data: 1165450-70-3(Hazardous Substances Data)

Usage

Uses

Used in Solvent Applications:
(4R)-4-(hydroxyMethyl)-2-Pyrrolidinone is used as a solvent in various industrial processes due to its ability to dissolve a wide range of substances.
Used in Corrosion Inhibition:
(4R)-4-(hydroxyMethyl)-2-Pyrrolidinone serves as a corrosion inhibitor, helping to protect materials from degradation and extending their lifespan.
Used in Radiation-Curable Coatings Industry:
(4R)-4-(hydroxyMethyl)-2-Pyrrolidinone is used as a reactive diluent in the production of radiation-curable coatings, enhancing the performance and application of these coatings.
Used in Polymer Production:
(4R)-4-(hydroxyMethyl)-2-Pyrrolidinone is utilized as a monomer in the synthesis of polyvinylpyrrolidone (PVP), a polymer with diverse applications in various industries.
Used in Pharmaceutical and Agrochemical Synthesis:
(4R)-4-(hydroxyMethyl)-2-Pyrrolidinone is employed in the synthesis of pharmaceuticals and agrochemicals, contributing to the development of new and improved products in these fields.
Used in Polymers, Resins, and Adhesives Production:
(4R)-4-(hydroxyMethyl)-2-Pyrrolidinone has potential applications in the production of polymers, resins, and adhesives, where its properties can be leveraged to create innovative materials with specific characteristics.

Upstream product

• 190957-22-3 (4R,1'R)-1-(1'-phenylethyl)-4-hydroxymethylpyrrolidin-2-one 
• 99735-43-0 (3R)-1-((R)-1-phenylethyl)-5-oxo-3-pyrrolidinecarboxylic acid 
• 192214-02-1 β-azidomethyl γ-butyrolactone 

Downstream Products

• 1319737-93-3 (R)-4-{7-[4-(tetrahydro-pyran-4-yloxy)-3-trifluoromethyl-phenyl]-[1,6]naphthyridine-5-yloxymethyl}pyrrolidine-2-one 
• 1319738-03-8 (R)-4-{7-[3-methoxy-4-(tetrahydro-pyran-4-yloxy)phenyl]-[1,6]naphthyridine-5-yloxymethyl}pyrrolidine-2-one 
• 1319738-12-9 (R)-4-[7-(3-Fluoro-4-isopropoxy-phenyl)-[1,6]naphthyridine-5-yloxy-methyl]-pyrrolidine-2-one 

Relevant articles and documents

3,4-Methano-β-proline: A conformationally constrained β-amino acid

An enantiomerically pure, conformationally constrained β-proline derivative, 3,4-methano-β-proline, was synthesized starting with a readily available bicyclic lactone by using a straightforward synthetic route.

SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS

The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein R1 is selected from among —O—R3 or —NR3R4,R3 is C1-6-alkyl which is substituted by R5 and R6,R5 is selected from hydrogen, branched or linear C1-6-alkyl, C2-6-alkenyl, —C1-6-alkylen-O—C1-3-alkyl, C1-3-haloalkyl,R6 is ring X wherein n is either 0 or 1, and is a either a single or a double bond andwherein A, B, D and E are each independently from one another selected from CH2, CH, C, N, NH, O or S and wherein ring X is attached to the molecule either via position A, B, D or E, wherein said ring X may optionally be further substituted by one, two or three residues each selected individually from the group consisting of -oxo, hydroxy, —C1-3-alkyl, —C1-3-haloalkyl, —O—C1-3-alkyl, —C1-3-alkanol and halogen,and wherein R4, R2, R7, R8, R9, R10, R11 and Q may have the meanings as given in claim 1, as well as pharmaceutical compositions containing these compounds.

SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS

The invention relates to new substituted naphthyridines of formula (1), as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein R1 is selected from among -O-R3 or -NR3R4, R3 is C1-6-alkyl which is substituted by R5 and R6 R5 is selected from hydrogen, branched or linear C1-6-alkyl, C2-6-alkenyl, -C1-6-alkylen-O-C1-3-alkyl, C1-3-haloalkyl, R6 is ring X wherein n is either 0 or 1, and Formula (I) is a either a single or a double bond and wherein A, B, D and E are each independently from one another selected from CH2, CH, C, N, NH, O or S and wherein ring X is attached to the molecule either via position A, B, D or E, wherein said ring X may optionally be further substituted by one, two or three residues each selected individually from the group consisting of -oxo, hydroxy, -C1-3-alkyl, -C1-3-haloalkyl, -O-C1-3-alkyl, -C1-3-alkanol and halogen, and wherein R4, R2, R7, R8, R9, R10, R11 and Q may have the meanings as given in claim 1, as well as pharmaceutical compositions containing these compounds.